-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
CNS Pharmaceuticals (NASDAQ:CNSP) & LumiraDx (NASDAQ:LMDX) Head-To-Head Comparison
CNS Pharmaceuticals (NASDAQ:CNSP) & LumiraDx (NASDAQ:LMDX) Head-To-Head Comparison
CNS Pharmaceuticals (NASDAQ:CNSP – Get Rating) and LumiraDx (NASDAQ:LMDX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for CNS Pharmaceuticals and LumiraDx, as provided by MarketBeat.com.
Get CNS Pharmaceuticals alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
CNS Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
LumiraDx | 0 | 1 | 2 | 0 | 2.67 |
CNS Pharmaceuticals presently has a consensus target price of $30.00, indicating a potential upside of 1,104.82%. LumiraDx has a consensus target price of $7.17, indicating a potential upside of 637.99%. Given CNS Pharmaceuticals' higher probable upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than LumiraDx.
Risk and Volatility
CNS Pharmaceuticals has a beta of 3.22, suggesting that its stock price is 222% more volatile than the S&P 500. Comparatively, LumiraDx has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.Insider and Institutional Ownership
3.0% of CNS Pharmaceuticals shares are held by institutional investors. 8.6% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares CNS Pharmaceuticals and LumiraDx's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
CNS Pharmaceuticals | N/A | -121.57% | -107.59% |
LumiraDx | -115.81% | -456.53% | -59.94% |
Valuation and Earnings
This table compares CNS Pharmaceuticals and LumiraDx's gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
CNS Pharmaceuticals | N/A | N/A | -$14.04 million | ($1.05) | -2.37 |
LumiraDx | $421.43 million | 0.10 | -$100.93 million | ($1.42) | -0.68 |
CNS Pharmaceuticals has higher earnings, but lower revenue than LumiraDx. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than LumiraDx, indicating that it is currently the more affordable of the two stocks.
Summary
CNS Pharmaceuticals beats LumiraDx on 8 of the 13 factors compared between the two stocks.
About CNS Pharmaceuticals
(Get Rating)
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
About LumiraDx
(Get Rating)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
CNS Pharmaceuticals (NASDAQ:CNSP – Get Rating) and LumiraDx (NASDAQ:LMDX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.
纳斯达克:CNSP-GET评级)和LumiraDx(纳斯达克:LMDX-GET评级)都是小盘医疗公司,但哪只股票更好?我们将根据这两家公司的风险、股息、收益、盈利能力、分析师建议、机构所有权和估值的强弱对它们进行比较。
Analyst Recommendations
分析师建议
This is a breakdown of current ratings and recommmendations for CNS Pharmaceuticals and LumiraDx, as provided by MarketBeat.com.
这是由MarketBeat.com提供的对CNS制药公司和LumiraDx的当前评级和推荐的细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
CNS Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
LumiraDx | 0 | 1 | 2 | 0 | 2.67 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
CNS制药公司 | 0 | 1 | 0 | 0 | 2.00 |
LumiraDx | 0 | 1 | 2 | 0 | 2.67 |
CNS Pharmaceuticals presently has a consensus target price of $30.00, indicating a potential upside of 1,104.82%. LumiraDx has a consensus target price of $7.17, indicating a potential upside of 637.99%. Given CNS Pharmaceuticals' higher probable upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than LumiraDx.
CNS PharmPharmticals目前的共识目标价为30.00美元,表明潜在上行空间为1104.82%。LumiraDx的一致目标价为7.17美元,表明潜在上行空间为637.99%。鉴于CNS PharmPharmticals上涨的可能性更大,股票研究分析师显然认为CNS PharmPharmticals比LumiraDx更有利。
Risk and Volatility
风险和波动性
Insider and Institutional Ownership
内部人与机构持股
3.0% of CNS Pharmaceuticals shares are held by institutional investors. 8.6% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
CNS制药3.0%的股份由机构投资者持有。CNS制药8.6%的股份由内部人士持有。强大的机构持股表明,对冲基金、大型基金管理公司和捐赠基金相信,一只股票有望实现长期增长。
Profitability
盈利能力
This table compares CNS Pharmaceuticals and LumiraDx's net margins, return on equity and return on assets.
此表比较了CNS制药公司和LumiraDx公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
CNS Pharmaceuticals | N/A | -121.57% | -107.59% |
LumiraDx | -115.81% | -456.53% | -59.94% |
净利润率 | 股本回报率 | 资产回报率 | |
CNS制药公司 | 不适用 | -121.57% | -107.59% |
LumiraDx | -115.81% | -456.53% | -59.94% |
Valuation and Earnings
估值和收益
This table compares CNS Pharmaceuticals and LumiraDx's gross revenue, earnings per share (EPS) and valuation.
该表格比较了CNS制药和LumiraDx的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
CNS Pharmaceuticals | N/A | N/A | -$14.04 million | ($1.05) | -2.37 |
LumiraDx | $421.43 million | 0.10 | -$100.93 million | ($1.42) | -0.68 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
CNS制药公司 | 不适用 | 不适用 | -1,404万元 | ($1.05) | -2.37 |
LumiraDx | 4.2143亿美元 | 0.10 | -1.093亿美元 | ($1.42) | -0.68 |
CNS Pharmaceuticals has higher earnings, but lower revenue than LumiraDx. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than LumiraDx, indicating that it is currently the more affordable of the two stocks.
CNS PharmPharmticals的收益高于LumiraDx,但营收低于LumiraDx。CNS PharmPharmticals的市盈率低于LumiraDx,表明它目前是两只股票中更负担得起的一只。
Summary
摘要
CNS Pharmaceuticals beats LumiraDx on 8 of the 13 factors compared between the two stocks.
在比较两只股票的13个因素中,CNS PharmPharmticals有8个超过LumiraDx。
About CNS Pharmaceuticals
关于CNS制药公司
(Get Rating)
(获取评级)
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNS制药公司是一家临床制药公司,致力于开发用于治疗大脑和中枢神经系统肿瘤的抗癌候选药物。该公司的主要候选药物是贝柔比星,这是一种正在进行I期和II期临床试验的蒽环类药物,用于治疗多形性胶质母细胞瘤。它与休斯顿制药公司和德克萨斯大学M.D.安德森癌症中心以及动物生命科学有限责任公司签订了许可协议;与WPD制药公司签订了开发协议,并与Reata制药公司达成了合作协议。该公司成立于2017年,总部位于德克萨斯州休斯顿。
About LumiraDx
关于LumiraDx
(Get Rating)
(获取评级)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.
LumiraDx有限公司是一家医疗诊断公司。该公司专注于通过向医疗保健提供者提供关键诊断信息来转变基于社区的医疗保健。它制造和销售一种诊断平台,该平台支持各种测试,在护理点具有实验室可比的性能。该公司已有大约30种测试进入市场并正在开发中,涵盖传染病、心血管疾病、糖尿病和凝血障碍,以及从实验室到需要的新冠肺炎测试解决方案组合。其诊断测试解决方案由政府和医疗机构在实验室、紧急护理、医生办公室、药房、学校和工作场所部署,以筛查、诊断和监测健康状况以及疾病。该公司成立于2014年,总部设在英国伦敦。
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受CNS医药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对CNS制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧